{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:33:59Z","timestamp":1793795639988,"version":"4.6.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Nausea and vomiting accompany pregnancy, gastroenteritis, migraine, the perioperative period, and cytotoxic chemotherapy, and antiemetics are among the most frequently prescribed drugs worldwide. Several antiemetic classes delay ventricular repolarization and prolong the QT interval, a substrate for torsades de pointes (TdP), ventricular fibrillation, and sudden cardiac death. We synthesized the evidence on antiemetic QT liability and translated it into a three-tier, risk-stratified prescribing framework and stepwise clinical algorithm for patients with inherited or acquired long QT syndrome (LQTS) and other torsadogenic risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a narrative review of PubMed\/MEDLINE, EMBASE, and pharmacovigilance sources (FDA Adverse Event Reporting System, CredibleMeds\/QTdrugs) through early 2026, prioritizing mechanistic studies, randomized comparisons, disproportionality analyses, and consensus statements on antiemetic QT liability and LQTS management.QT prolongation across antiemetic classes is driven principally by IKr blockade (hERG\/KCNH2). Risk is highly heterogeneous within classes: in a 2026 FAERS disproportionality analysis, ondansetron carried a substantially stronger QT-related signal than olanzapine (reporting odds ratio 27.2 vs. 8.7), consistent with its dose-dependent effect among 5-HT3 antagonists, which prompted a 2012 FDA restriction on the 32 mg intravenous dose; palonosetron has minimal effect. Neurokinin-1 antagonists, low-risk antihistamines, anticholinergics, and 5-HT4 agonists carry little QT liability, while butyrophenones, phenothiazines, and promethazine carry greater risk. Serious events cluster in patients with electrolyte disturbance, bradycardia, polypharmacy, or underlying LQTS, particularly when QTc exceeds 500 ms or rises more than 60 ms from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Antiemetic-associated arrhythmia is largely preventable. Structured risk assessment, electrolyte correction, ECG monitoring, and a stepwise selection strategy favouring agents with minimal QT liability allow clinicians to manage nausea and vomiting safely, even in high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag077","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:07:09Z","timestamp":1789474029000},"page":"556-567","source":"Crossref","is-referenced-by-count":1,"title":["Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8507-2729","authenticated-orcid":false,"given":"Ahmed T","family":"Moustafa","sequence":"first","affiliation":[{"name":"London Health Sciences Centre Research Institute, Western University , London, Ontario N6G5A5 ,","place":["Canada"]},{"name":"Western University Schulich School of Medicine and Dentistry, , London, Ontario N6G5A5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4521-2493","authenticated-orcid":false,"given":"Omar","family":"Dabash","sequence":"additional","affiliation":[{"name":"Royal College of Surgeons in Ireland , Dublin, D02YN77 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-4141","authenticated-orcid":false,"given":"Pradosh Kumar","family":"Panigrahi","sequence":"additional","affiliation":[{"name":"Western University Schulich School of Medicine and Dentistry, , London, Ontario N6G5A5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-5768","authenticated-orcid":false,"given":"Habib Rehman","family":"Khan","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre Research Institute, Western University , London, Ontario N6G5A5 ,","place":["Canada"]},{"name":"Western University Schulich School of Medicine and Dentistry, , London, Ontario N6G5A5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026110318520876000_pvag077-B1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/1756283X15618131","article-title":"Nausea: a review of pathophysiology and therapeutics","volume":"9","author":"Singh","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"2026110318520876000_pvag077-B2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115797","article-title":"Mechanisms of nausea and vomiting: current knowledge and recent advances in intracellular emetic signaling systems","volume":"22","author":"Zhong","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026110318520876000_pvag077-B3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"2026110318520876000_pvag077-B4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1213\/ANE.0000000000004833","article-title":"Fourth consensus guidelines for the management of postoperative nausea and vomiting","volume":"131","author":"Gan","year":"2020","journal-title":"Anesth Analg"},{"key":"2026110318520876000_pvag077-B5","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026110318520876000_pvag077-B6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","article-title":"Drug-induced long QT syndrome","volume":"62","author":"Kannankeril","year":"2010","journal-title":"Pharmacol Rev"},{"key":"2026110318520876000_pvag077-B7","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.613625","article-title":"QT prolongation in cancer patients","volume":"8","author":"Kim","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026110318520876000_pvag077-B8","doi-asserted-by":"crossref","first-page":"25738","DOI":"10.18632\/oncotarget.25008","article-title":"Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives","volume":"9","author":"Duan","year":"2018","journal-title":"Oncotarget"},{"key":"2026110318520876000_pvag077-B9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad Med J"},{"key":"2026110318520876000_pvag077-B10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/15360288.2021.1900491","article-title":"The risk of QTc prolongation with antiemetics in the palliative care setting: anarrative review","volume":"35","author":"Gavioli","year":"2021","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026110318520876000_pvag077-B11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ccep.2016.01.004","article-title":"Cardiac delayed rectifier potassium channels in health and disease","volume":"8","author":"Chen","year":"2016","journal-title":"Card Electrophysiol Clin"},{"key":"2026110318520876000_pvag077-B12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","article-title":"QT interval: how to measure it and what is \u201cnormal\u201d","volume":"17","author":"Goldenberg","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026110318520876000_pvag077-B13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"key":"2026110318520876000_pvag077-B14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026110318520876000_pvag077-B15","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/01.CIR.94.8.1996","article-title":"Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS foundation task force on LQTS","volume":"94","author":"Roden","year":"1996","journal-title":"Circulation"},{"key":"2026110318520876000_pvag077-B16","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1172\/JCI25539","article-title":"Genetics of acquired long QT syndrome","volume":"115","author":"Roden","year":"2005","journal-title":"J Clin Invest"},{"key":"2026110318520876000_pvag077-B17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cpcardiol.2008.07.002","article-title":"Long QT syndrome","volume":"33","author":"Goldenberg","year":"2008","journal-title":"Curr Probl Cardiol"},{"key":"2026110318520876000_pvag077-B18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/heartjnl-2020-318259","article-title":"Diagnosis, management and therapeutic strategies for congenital long QT syndrome","volume":"108","author":"Wilde","year":"2022","journal-title":"Heart"},{"key":"2026110318520876000_pvag077-B19","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.109.863209","article-title":"Prevalence of the congenital long-QT syndrome","volume":"120","author":"Schwartz","year":"2009","journal-title":"Circulation"},{"key":"2026110318520876000_pvag077-B20","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1113\/JP270526","article-title":"Predicting drug-induced QT prolongation and torsades de pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J Physiol"},{"key":"2026110318520876000_pvag077-B21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2344\/0003-3006-57.4.150","article-title":"Nausea, vomiting, and hiccups: a review of mechanisms and treatment","volume":"57","author":"Becker","year":"2010","journal-title":"Anesth Prog"},{"key":"2026110318520876000_pvag077-B22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0022-3565(24)38946-3","article-title":"Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels","volume":"295","author":"Kuryshev","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2026110318520876000_pvag077-B23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.annemergmed.2013.10.026","article-title":"Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis","volume":"64","author":"Freedman","year":"2014","journal-title":"Ann Emerg Med"},{"key":"2026110318520876000_pvag077-B24","doi-asserted-by":"crossref","first-page":"214.e3","DOI":"10.1016\/j.ajem.2023.04.003","article-title":"QT prolongation, torsades des pointes, and cardiac arrest after 4 mg of IV ondansetron","volume":"68","author":"Orozco","year":"2023","journal-title":"Am J Emerg Med"},{"key":"2026110318520876000_pvag077-B25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10557-025-07766-2","article-title":"Morbidity and mortality of ondansetron in patients with non-congenital long QT syndrome: areview article","volume":"40","author":"Al-Ramadan","year":"2026","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026110318520876000_pvag077-B26","doi-asserted-by":"crossref","first-page":"1748635","DOI":"10.3389\/fphar.2026.1748635","article-title":"QT-related adverse events with ondansetron and olanzapine: a real-world FAERS analysis with implications for oncology anti-emetic practice","volume":"17","author":"Gandhi","year":"2026","journal-title":"Front Pharmacol"},{"key":"2026110318520876000_pvag077-B27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/CMAR.S34352","article-title":"Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management","volume":"5","author":"Mason","year":"2013","journal-title":"Cancer Manag Res"},{"key":"2026110318520876000_pvag077-B28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/00000542-200506000-00006","article-title":"Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron","volume":"102","author":"Charbit","year":"2005","journal-title":"Anesthesiology"},{"key":"2026110318520876000_pvag077-B29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1213\/ane.0b013e3181ac1066","article-title":"Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects","volume":"109","author":"Marbury","year":"2009","journal-title":"Anesth Analg"},{"key":"2026110318520876000_pvag077-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.respe.2016.06.335","article-title":"Reseau francais des centres regionaux de p. [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: case\/non-case analysis in the national pharmacovigilance database]","volume":"65","author":"Rochoy","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2026110318520876000_pvag077-B31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41598-020-79380-1","article-title":"Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QT(C) interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study","volume":"11","author":"Kamath","year":"2021","journal-title":"Sci Rep"},{"key":"2026110318520876000_pvag077-B32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0019-5049.108560","article-title":"Comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: a prospective single-blind randomised trial","volume":"57","author":"Ganjare","year":"2013","journal-title":"Indian J Anaesth"},{"key":"2026110318520876000_pvag077-B33","doi-asserted-by":"crossref","DOI":"10.2196\/65872","article-title":"Detection of clinically significant drug-drug interactions in fatal torsades de pointes: disproportionality analysis of the food and drug administration adverse event reporting system","volume":"27","author":"Ji","year":"2025","journal-title":"J Med Internet Res"},{"key":"2026110318520876000_pvag077-B34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40264-017-0519-0","article-title":"Adverse drug event causality analysis (ADECA): aprocess for evaluating evidence and assigning drugs to risk categories for sudden death","volume":"40","author":"Woosley","year":"2017","journal-title":"Drug Saf"},{"key":"2026110318520876000_pvag077-B35","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2026110318520876000_pvag077-B36","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","article-title":"The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview","volume":"23","author":"Giraud","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026110318520876000_pvag077-B37","author":"National Comprehensive Cancer Network"},{"key":"2026110318520876000_pvag077-B38","first-page":"53","article-title":"Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation","volume":"32","author":"Jordan","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026110318520876000_pvag077-B39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115451","article-title":"Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"222","author":"Jordan","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026110318520876000_pvag077-B40","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026110318520876000_pvag077-B41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.hrthm.2022.03.1225","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases","volume":"19","author":"Wilde","year":"2022","journal-title":"Heart Rhythm"},{"key":"2026110318520876000_pvag077-B42","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae216","article-title":"Genetic testing for inherited arrhythmia syndromes and cardiomyopathies: results of the European heart Rhythm Association survey","volume":"26","author":"Zeljkovic","year":"2024","journal-title":"Europace"},{"key":"2026110318520876000_pvag077-B43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/phar.2087","article-title":"Validation and clinical utility of the hERG IC50:C(max) ratio to determine the risk of drug-induced torsades de pointes: ameta-analysis","volume":"38","author":"Lehmann","year":"2018","journal-title":"Pharmacotherapy"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag077\/71130347\/pvag077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/7\/556\/71130347\/pvag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/7\/556\/71130347\/pvag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:52:16Z","timestamp":1793749936000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/7\/556\/8802565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag077","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,16]]}}}